Genentech

Opthea, an Australian clinical stage biotech company, is going public to help fund its Phase 3 trials and take on two large biotech companies. About Opthea: The main area of focus for Opthea Ltd (NASDAQ: OPT) is wet age-related macular degeneration, commonly referred to as AMD, and other...

Shares of Swiss biopharma AC Immune SA (NASDAQ: ACIU) have lost about half their market capitalization on an adverse clinical readout for an out-licensed investigational Alzheimer's drug. What Happened: AC Immune's licensing partner Roche Holdings AG's Basel ADR Common Stock (...

Shares of Proteostasis Therapeutics Inc (NASDAQ: PTI) were moving higher Monday after the clinical stage biopharmaceutical company announced a worldwide exclusive license agreement with Roche Group's Genentech unit. What Happened Proteostasis Therapeutics develops therapies for the...

Affimed NV (NASDAQ: AFMD) shares are trading sharply higher Tuesday after the biopharma announced a collaboration agreement with Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY)'s Genentech unit. Affimed shares were skyrocketing 148.7 percent to $3.98 at the time of publication...

Orphan drugs, drugs intended to prevent, diagnose or treat rare diseases/disorders, are huge sellers for the pharmaceutical industry. NPR, citing data from EvaluatePharma, noted that seven of the 10 best-selling drugs in the United States throughout 2015 were given an orphan drug status. The main...

Shares of AC Immune Ltd (NASDAQ: ACIU), a medical biotechnology company that focuses on the treatment of Alzheimer's disease (AD) and other neurodegenerative diseases, soared higher by more than 23 percent after the company's partner Genentech published an editorial. AC Immune and Genentech have...

The biotechnology industry had a big day Monday after the news of Swiss pharmaceutical giant Roche agreed to acquire the U.S biotech company InterMune (NASDAQ: ITMN) for $8.3 billion in cash. The deal breaks down to Roche paying $74.00 a share for InterMune, a 38 percent premium from its...

Google (NASDAQ: GOOG) announced the creation of Calico – whose goal is to “generally improve people’s lives.” Many details on Calico are being kept under wraps, stating the project is still in its early stages. The Google+ post made this Wednesday by the Google CEO Larry Page indicated that...